Ascendis Pharma Revenue More Than Doubles on YORVIPATH Strength, YUVIWEL Launch Momentum
Danish biopharma reports Q2 total revenue of €339 million as flagship hypoparathyroidism therapy reaches blockbuster run rate and achondroplasia treatment sees rapid adoption.
YORVIPATH Reaches Blockbuster Status
Ascendis Pharma A/S reported total revenue of €339 million for the second quarter of 2026, with product revenue of €315 million more than doubling year-over-year (earnings call, 2026-08-13). The Danish biopharma company's performance was driven primarily by YORVIPATH, its hypoparathyroidism treatment, which generated €252 million in quarterly revenue.
YORVIPATH, the first approved therapy that addresses hypoparathyroidism by replacing missing endogenous parathyroid hormone, has reached "blockbuster status on a run rate basis in the second year of launch in the U.S.," according to Chief Financial Officer Scott Smith (earnings call, 2026-08-13). The drug is now available commercially or through named patient programs in more than 35 countries.
CEO Jan Mikkelsen highlighted the therapy's clinical performance, noting "sustained response rate of 82% to 86% for the multi-covenant endpoint with clinical benefit across multiple organ systems" and "patient retention as high as 95% after 5 years" (earnings call, 2026-08-13). The company is targeting a market of more than 800,000 patients living with hypoparathyroidism in regions covered by its commercial infrastructure.
YUVIWEL Launch Accelerates
The company's achondroplasia treatment YUVIWEL demonstrated rapid adoption since its U.S. launch. Through June 30, the therapy had enrolled more than 170 unique patients, a figure that grew to "more than 220 enrollment and more than 65% approved for reimbursement in the U.S. through the end of July" (earnings call, 2026-08-13).
Mikkelsen characterized the launch as "really and unique," noting that uptake includes both treatment-naive patients and those switching from other therapies. "We believe YUVIWEL is really growing the U.S. market," he added (earnings call, 2026-08-13). The company expects a regulatory decision for YUVIWEL in the European Union during the fourth quarter of 2026.
Ascendis is also advancing a combination therapy pairing YUVIWEL (TransCon CNP) with its growth hormone product SKYTROFA. The company's COS clinical trial showed "sustained transformative to annualized growth velocity" with the combination over 78 weeks (earnings call, 2026-08-13). Phase III combination trials are slated to begin enrollment later this year.
SKYTROFA and Pipeline Progress
SKYTROFA, the company's once-weekly growth hormone treatment, contributed €55 million in second-quarter revenue and recently surpassed 20,000 unique patient enrollments (earnings call, 2026-08-13). The product remains "the #1 long-acting growth hormone by brand value in the U.S.," according to Mikkelsen (earnings call, 2026-08-13).
Total revenue for the quarter included €24 million in nonproduct collaboration revenue, which featured a €17 million milestone payment related to TransCon CNP (earnings call, 2026-08-13).
The company is expanding its pipeline through partnerships, including a once-monthly semaglutide program with Novo Nordisk and an anti-VEGF ophthalmology treatment that recently initiated first-in-human trials. Ascendis also plans to expand YORVIPATH's label to include patients aged 12 to 18 years and is developing a once-weekly formulation for stable-dose patients.
MarginX data shows recent insider purchases by CFO Scott Smith and board member Jean Jacques Bienaime, though the company provided no commentary on these transactions during the earnings call.
This article was generated by MarginX from the earnings call on 2026-08-13. It is not investment advice.